As Service and Support Director at Xiogenix, I have the privilege of spending a great deal of time on the road visiting tissue banks across the country. Because of that, I get to see firsthand the incredible work being done every day in regenerative health. I see the...

Each year, industry leaders across biotech, pharma, and advanced manufacturing gather at Advanced Therapies Week, hosted by Phacilitate, to discuss the future of cell and gene therapy. Held in San Diego, the conference serves as one of the most influential global...

Tissue banking demands precision, consistency, and regulatory discipline. Every donor gift must be processed with care, yet many workflows still rely heavily on manual steps that introduce variability, increase ergonomic strain, and complicate documentation. As demand...

In cell and gene therapy, teams devote significant time and resources to optimizing upstream and downstream processes. Yet many programs encounter unexpected challenges during the final stage: fill and finish. This step often determines whether a batch is released on...

Why Speed Matters in Allogeneic Cell Therapy Fill & FinishAnd how faster filling protects product quality, reduces risk, and improves scalabilityAs allogeneic (“off the shelf”) cell therapies continue to expand, manufacturing teams face a clear challenge: produce...

As tissue banking continues to scale, precision and consistency are becoming just as critical as compliance. Whether processing dermis, amnion, or other soft tissues, banks are being asked to deliver uniform grafts while operating under tighter cleanroom controls and...

Cell and gene therapy developers continually encounter significant hurdles during the fill & finish phase—challenges best illustrated by manual workflows that are prone to variability, risk of contamination, and limited scalability. This whitepaper, authored by...